id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7663 R22687 |
Tomson (Valproate), 2018 | Hypospadias | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 6.77 [2.74;16.73] C | 22/1,381 6/2,514 | 28 | 1,381 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S318 R14438 |
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 | Hypospadias and genitourinary tract defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.60 [1.16;5.81] | 15/1,220 10/2,098 | 25 | 1,220 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5940 R23798 |
Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 | Hypospadias | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 54.10 [2.98;980.87] C | 5/323 0/1,562 | 5 | 323 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6505 R17911 |
Bànhidy (Valproate), 2011 | Hypospadias | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 2.00 [0.29;13.74] C | 3/8 3/13 | 6 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6687 R18646 |
D'Souza (Valproate) (Controls unexposed, disease free), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
123.00 [1.00;15058.31] C excluded (control group) |
0/1 0/62 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6695 R18807 |
D'Souza (Valproate) (Controls unexposed, sick), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 15.00 [0.12;1923.88] C | 0/1 0/8 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 4.64 [2.00;10.77] | 64 | 2,933 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate; 2: Valproate) (Controls exposed to Lamotrigine, sick; 3: Valproate) (Controls exposed to Lamotrigine, sick; 4: Valproate; 5: Valproate) (Controls unexposed, sick;
Asymetry test p-value = 0.4291 (by Egger's regression)
slope=0.8872 (0.7034); intercept=1.0045 (1.1016); t=0.9119; p=0.4291
excluded 6687